The biotech and medtech sectors are buzzing with excitement in 2024, thanks to a wave of innovation and promising developments that have captured the attention of investors and industry experts alike. Groundbreaking advancements in diabetes treatments and a surge in mergers and acquisitions are driving a renaissance in the healthcare industry, fueled by cutting-edge technologies and a renewed focus on patient-centric solutions. While many high-growth stocks in these sectors trade at premium valuations, there are still some hidden gems trading at relatively low prices that could potentially bre…